Medical News

RSS

AHF calls on FDA Commissioner Hamburg to step down

AIDS Healthcare Foundation (AHF), the nation's largest HIV/AIDS organization, today called on Food and Drug Administration (FDA) Commissioner Margaret Hamburg to step down in response to the agency's gross mismanagement of new product reviews and a lack of transparency.

29 Mar 2012

Chromosomal abnormality in children with ependymoma linked with poorer chance of survival

A chromosomal abnormality in children with a deadly form of brain cancer is linked with a poorer chance of survival, clinician scientists at The University of Nottingham have discovered.

29 Mar 2012

ASGE announces honorees of new endoscopy unit recognition program

The American Society for Gastrointestinal Endoscopy (ASGE) has recognized 18 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States.

29 Mar 2012

Losing weight and increasing physical activity reduces decline in mobility in obese adults with type 2 diabetes

Weight loss and increased physical fitness nearly halved the decline in mobility in overweight or obese adults with type 2 diabetes, according to four-year results of the Look AHEAD (Action for Health in Diabetes) trial funded by the National Institutes of Health.

29 Mar 2012

Henry Schein launches Dentrix G5 practice management system

Henry Schein Inc., the largest provider of health care products and services to dental, medical and animal health office-based practitioners, today announced the launch of Dentrix G5, a new version of the Dentrix practice management system.

29 Mar 2012

LivHOME introduces LivIndependa for older adults

LivHOME, Inc., one of the nation's largest providers of professionally led at-home care for seniors, today announced the launch of LivIndependa, a tablet-computer based remote care service for older adults.

29 Mar 2012

Mylan receives FDA approval for generic Seroquel ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Inhibitory control test and lactulose for MHE saves more than $3 million over 5 years

A late stage liver condition, known as minimal hepatic encephalopathy (MHE), is associated with impaired driving skills and greater risk of motor vehicle accidents. Cost analysis of management strategies for detection and treatment of MHE are published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2012

Merrimack prices initial public offering of 14,300,000 shares of common stock

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.

29 Mar 2012

Enrollment complete in Aperion Biologics' Z-Lig Anterior Cruciate Ligament Reconstruction Device trial

Aperion Biologics, Inc. announced that it has completed patient enrollment and implantation in the Company's clinical trial of its Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee.

29 Mar 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

Helix BioMedix 2011 revenue increases 122% to record $1.9 million

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the year ended December 31, 2011.

29 Mar 2012

People with AN consume more of test meal in vodcast condition

There is uncertainty about the best form of treatment for anorexia nervosa (AN). A report that is published in the current issue of Psychotherapy and Psychosomatics introduces a new treatment modality.

29 Mar 2012

EU-funded project to help control appetite, combat obesity

The University of Liverpool is leading a £6milllion European project to develop and test new food products with satiating qualities to help control appetite, manage weight and combat obesity.

29 Mar 2012

Discontinuance of statin therapy increases CVD mortality risk in RA patients

Patients with rheumatoid arthritis (RA) who discontinue use of statin therapy are at increased risk of death from cardiovascular disease and other causes.

29 Mar 2012

Pernix fourth quarter net revenues increase 74% to $21.4 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced financial results for the quarter and year ended December 31, 2011.

29 Mar 2012

FDA approves Avioq HTLV-I/II Microelisa System

Avioq, Inc. announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Avioq HTLV-I/II Microelisa System. The test is used for the qualitative detection of antibodies to Human T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type II (HTLV-II) in human serum or plasma.

29 Mar 2012

Political cartoon: 'Spring Forward, Fall Back?'

Kaiser Health News provides a fresh take on health policy developments with "Spring Forward, Fall Back?" by Chris Weyant.

29 Mar 2012

Heart attack could be treated best with cheap mix of three injections: Study

When the shot was given early to patients with signs of a heart attack, the mixture of glucose, insulin and potassium (GIK), showed remarkable success in preventing full cardiac arrest - when the heart stops beating - and even death. And each shot cocktail costs only about $US50, according to the research presented at the American College of Cardiology's 61st annual scientific meeting in Chicago. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.

28 Mar 2012